The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion.
Open accessAbstract
Twenty-seven cases of inflammatory breast cancer were screened for the presence of the p53 protein by immunocytochemical methods using a monoclonal antibody directed against the p53 protein. Three groups were detected: 8 cases (30%) had high levels of p53 in the nucleus of the cancer cells; 9 cases (33%) had a complete lack of detectable staining; 10 cases (37%) showed a pattern of cytoplasmic staining with nuclear sparing. Nucleotide sequence analysis of p53 cDNAs derived from the samples with cytoplasmic staining revealed only wild-type p53 alleles in 6 out of 7 cases. An eighth case was determined to be wild type by a single-strand conformation polymorphism. In contrast, the samples containing nuclear p53 contained a variety of missense mutations and a nonsense mutation. The p53 cDNAs from 3 of the tumors that lacked detectable p53 staining were analyzed, and all 3 had wild-type nucleotide sequences. Interestingly, a case of normal lactating breast tissue also showed intense cytoplasmic staining for p53 with nuclear sparing. These data suggest that some breast cancers that contain the wild-type form of p53 protein may inactivate its tumor-suppressing activity by sequestering this protein in the cytoplasm, away from its site of action in the cell nucleus. The detection of cytoplasmic p53 in normal lactating breast tissue could suggest that this is the mechanism employed in specific physiological situations to permit transient cell proliferation. This observation could explain how some breast cancer tissues inactivate p53 function without mutation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“constitutive-cytoplasmic sequestration of p53 occurs in inflammatory breast cancer,11,12 neuroblastoma,13 retinoblastoma and some colon carcinomas14 and correlates with poor prognosis and resistance to therapy.”
From Stress-mediated nuclear stabilization of p53 is regulated by ubiquitination and importin-α3 binding (2010) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primer-Directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase
Saiki, R. K., Gelfand, D. H., Stoffel, S., Scharf, S. J., Higuchi, R., Horn, G. T., Mullis, K. B., & Erlich, H. A. (1988) · Science · doi:10.1126/science.2448875 · Cited by 17,719
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Self-citationOrita, M., Suzuki, Y., Sekiya, T., & Hayashi, K. (1989) · Genomics · doi:10.1016/0888-7543(89)90129-8 · Cited by 3,434
Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas
Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., et al. (1989) · Science · doi:10.1126/science.2649981 · Cited by 2,066
The p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987
Self-citationSuppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p53
Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. V., & Vogelstein, B. (1990) · Science · doi:10.1126/science.2144057 · Cited by 1,754
Baker, S. J., Preisinger, A. C., Jessup, J. M., Paraskeva, C., Markowitz, S. D., Willson, J. K. V., Hamilton, S. R., & Vogelstein, B. (1990) · PubMed · Cited by 1,063
p53 functions as a cell cycle control protein in osteosarcomas.
Diller, L., Kassel, J., Nelson, C. E., Gryka, M. A., Litwak, G., Gebhardt, M., Bressac, B., Ozturk, M., Baker, S. J., & Vogelstein, B. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.11.5772 · Cited by 772
Michalovitz, D., Halevy, O., & Oren, M. (1990) · Cell · doi:10.1016/0092-8674(90)90113-s · Cited by 769
Wild-type p53 can inhibit oncogene-mediated focus formation.
Eliyahu, D., Michalovitz, D., Eliyahu, S., Pinhasi-Kimhi, O., & Oren, M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.22.8763 · Cited by 692
Gannon, J. V., Greaves, R., Iggo, R., & Lane, D. P. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb08279.x · Cited by 688
Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein.
Martinez, J., Georgoff, I., Martinez, J., & Levine, A. J. (1991) · Genes & Development · doi:10.1101/gad.5.2.151 · Cited by 527
Self-citationGenetic Mechanisms of Tumor Suppression by the Human p53 Gene
Chen, P.-L., Chen, Y., Bookstein, R., & Lee, W.-H. (1990) · Science · doi:10.1126/science.2274789 · Cited by 518
BANKS, L., MATLASHEWSKI, G., & CRAWFORD, L. (1986) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1986.tb09919.x · Cited by 495
Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells.
Oren, M., Maltzman, W., & Levine, A. J. (1981) · Molecular and Cellular Biology · doi:10.1128/mcb.1.2.101 · Cited by 489
Self-citationMercer, W. E., Shields, M. T., Amin, M., Sauve, G. J., Appella, E., Romano, J. W., & Ullrich, S. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.16.6166 · Cited by 477
Hinds, P. W., Finlay, C. A., Quartin, R. S., Baker, S. J., Fearon, E. R., Vogelstein, B., & Levine, A. J. (1990) · PubMed · Cited by 476
Self-citationPesce, A. J., & Kaplan, L. A. (1987) · Mosby eBooks · Cited by 452
Shaulsky, G., Goldfinger, N., Ben-Ze'ev, A., & Rotter, V (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.12.6565 · Cited by 356
Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2.
Bischoff, J. R., Friedman, P. N., Marshak, D. R., Prives, C., & Beach, D. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.12.4766 · Cited by 342
Midgley, C. A., Fisher, C. J., Bártek, J., Vojtések, B., Lane, D., & Barnes, D. M. (1992) · Journal of Cell Science · doi:10.1242/jcs.101.1.183 · Cited by 330
Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53.
Reich, N. C., Oren, M., & Levine, A. J. (1983) · Molecular and Cellular Biology · doi:10.1128/mcb.3.12.2143 · Cited by 312
Self-citationGenetic basis for p53 overexpression in human breast cancer.
Davidoff, A. M., Humphrey, P. A., Iglehart, J. D., & Marks, J. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.11.5006 · Cited by 285
Nuclear localization is essential for the activity of p53 protein.
Shaulsky, G., Goldfinger, N., Tosky, M. S., Levine, A. J., & Rotter, V. (1991) · PubMed · Cited by 192
Self-citationConstant denaturant gel electrophoresis as a rapid screening technique for p53 mutations.
Børresen, A. L., Hovig, E., Smith-Sørensen, B., Malkin, D., Lystad, S., Andersen, T. I., Nesland, J. M., Isselbacher, K. J., & Friend, S. H. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.19.8405 · Cited by 190
Cannon, J. V., & Lane, D. P. (1991) · Nature · doi:10.1038/349802a0 · Cited by 173
Evidence that p53 behaves as a tumour suppressor gene in sporadic breast tumours.
Prosser, J., Thompson, A. M., Cranston, G., & Evans, H. J. (1990) · PubMed · Cited by 167
p53 interacts with p34cdc2 in mammalian cells: implications for cell cycle control and oncogenesis.
Hw, S., Maimets, T., Chumakov, P. M., Brain, R., Addison, C. M., Simanis, V., Rudge, K., Philp, R. J., Grimaldi, M., & Court, W. J. (1990) · PubMed · Cited by 155
Ginsberg, D., Michael, D., Ginsberg, D., & Oren, M. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.1.582 · Cited by 142
Proteins controlling the nuclear uptake of NF-κB, Rel and dorsal
Schmitz, M. L., Henkel, T., & Baeuerle, P. A. (1991) · Trends in Cell Biology · doi:10.1016/0962-8924(91)90118-s · Cited by 104
Involvement of wild-type p53 protein in the cell cycle requires nuclear localization.
Shaulsky, G., Goldfinger, N., Peled, A., & Rotter, V. (1991) · PubMed · Cited by 53
Cited by
The complexity of p53 modulation: emerging patterns from divergent signals
Giaccia, A. J., & Kastan, M. B. (1998) · Genes & Development · doi:10.1101/gad.12.19.2973 · Cited by 1,314
p53 and Human Cancer: The First Ten Thousand Mutations
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60785-x · Cited by 986
Stommel, J. M., Marchenko, N. D., Jimenez, G. S., Moll, U. M., Hope, T. J., & Wahl, G. M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.6.1660 · Cited by 738
Self-citationTwenty years of p53 research: structural and functional aspects of the p53 protein
May, P., & May, E. (1999) · Oncogene · doi:10.1038/sj.onc.1203285 · Cited by 663
A Proinflammatory Cytokine Inhibits P53 Tumor Suppressor Activity
Hudson, J. D., Shoaibi, M. A., Maestro, R., Carnero, A., Hannon, G. J., & Beach, D. H. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.10.1375 · Cited by 649
Metadata
- Authors
- Moll, U. M., Riou, G., & Levine, A. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1992-08
- Volume
- 89
- Issue
- 15
- Pages
- 7262-7266
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1997646834
- Cited by
- 575
- References
- 32
- FWCI
- 15.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.